Telehealth appointments for chronic pain: what patients should expect

State law permits qualified prescribers to issue certain controlled-substance prescriptions through telehealth, while restricting Schedule II prescribing for chronic pain except in specific circumstances. The distinction matters before the visit: an appointment may be clinically useful even when the clinician cannot legally provide the prescription a patient expects.

Preparing for a Florida telehealth appointment for chronic pain therefore means more than testing a camera or listing medications. Patients should be ready to describe how the pain began and changed, discuss prior treatment, and understand that the clinician’s prescribing options depend on the drug’s schedule, the clinical assessment, and Florida’s statutory requirements. A video visit is an evaluation—not a promise of a particular diagnosis or prescription.

Florida’s prescribing rules set limits on the visit

Florida law allows telehealth providers to prescribe Schedule III, IV, and V controlled substances when the clinician is qualified and the applicable requirements are met. That permission does not mean every clinician will prescribe these medications, or that telehealth removes the usual need for a sound clinical rationale. A prescriber still has to assess the patient and decide whether a medication is appropriate.

Schedule II controlled substances are treated differently. Under Florida Statute § 456.47, a telehealth provider generally may not prescribe a Schedule II drug unless a statutory exception applies. The exceptions include treatment of a psychiatric disorder, a hospital inpatient, a hospice patient, or a nursing-home resident. Routine chronic-pain treatment by video is not, by itself, an exception.

This has practical consequences for a patient seeking a refill or a new prescription. If the medication is Schedule II, a telehealth appointment alone may not satisfy the applicable conditions. The clinician may need to arrange an in-person evaluation or direct the patient to an appropriate care setting. Patients should not assume that a prior prescription, an established clinician-patient relationship, or a detailed video consultation overrides the restriction.

The law is one part of the decision; clinical judgment is another. A medication may be legally prescribable through telehealth but still be unsuitable for an individual patient. Conversely, a clinician may be able to assess symptoms, review treatment goals, discuss noncontrolled options, or coordinate an in-person examination without issuing a controlled-substance prescription.

Telehealth can extend the assessment; it does not erase the prescribing rules that apply to the medication.

Florida’s approach should also be distinguished from broader assumptions about telemedicine. Rules vary by jurisdiction, and a patient who has received a prescription during a remote visit elsewhere should not infer that Florida permits the same process. For the appointment, the relevant questions are what Florida law allows, what the clinician’s practice protocol requires, and what the patient’s clinical situation supports.

What counts as a telehealth consultation

Florida defines telehealth around the use of telecommunications technology for health care. Standard telehealth consultations generally require audio and video; email and fax are explicitly excluded as substitutes for a telehealth encounter under the statute. A message exchange may help with scheduling or sharing records, but it does not become a clinical video assessment simply because it concerns symptoms.

Before the visit, patients should confirm how the practice will conduct the appointment and what to do if the connection fails. A stable connection, a private location, and a device with a working camera and microphone make it easier for the clinician to conduct the encounter. These are practical steps, not guarantees that a particular examination can be completed remotely.

Some aspects of a pain assessment can be discussed over video: the location and character of pain, its effect on sleep and daily activity, changes over time, and response to previous treatments. But remote evaluation has limits. A clinician cannot reproduce every element of an in-person examination, and some findings may require direct observation, touch, imaging, laboratory tests, or another assessment. If the available information is insufficient, an in-person visit may be the clinically appropriate next step rather than a failure of telehealth.

Patients should also clarify whether the appointment is intended for an initial evaluation, follow-up, medication review, or care coordination. Those purposes can call for different records and different decisions. A follow-up focused on response to an established treatment is not interchangeable with an initial assessment of new or worsening pain.

Prepare a clear record of the pain and its treatment

A useful remote assessment depends partly on what the clinician can verify and partly on what the patient can explain. Preparation is not about assembling an impressive file; it is about reducing gaps that could affect the assessment.

Before the appointment, gather or write down:

• A brief timeline: when the pain began, whether it followed an injury or procedure, and how it has changed.
• Location and pattern: where the pain occurs, whether it spreads, what tends to worsen or ease it, and whether it is constant or intermittent.
• Functional effects: specific activities affected, such as walking, sleeping, working, or completing routine tasks.
• Treatment history: medications tried, other therapies, perceived benefit, side effects, and reasons a treatment was stopped.
• Current medication details: names, doses if known, how they are taken, and which clinician prescribed them.
• Relevant records: prior evaluations, procedure information, imaging or test results, and the names of clinicians involved in the patient’s care.

A concise account is usually more clinically useful than a long narrative without dates or treatment details. If the patient does not know an exact medication dose or date, it is better to say so than to guess. The clinician can determine whether additional records are needed.

Patients should describe changes since the last evaluation, including new symptoms or a substantial change in function. They should also report medication-related problems and other treatments being used. Omitting relevant information can make it harder to assess benefit, risk, or whether a different evaluation is necessary.

The patient’s account is important, but it is not the only evidence in a clinical decision. A prescriber may review prior records, examine the patient remotely within the limits of the encounter, and request further assessment. That is particularly relevant when the symptoms are new, the diagnosis is uncertain, or the requested treatment carries additional prescribing requirements.

E-FORCSE and controlled-substance review

Florida prescribers are required to review the state’s Prescription Drug Monitoring Program, known as E-FORCSE, before issuing controlled-substance prescriptions. The purpose of this review is to give the prescriber information about controlled-substance dispensing recorded in the monitoring program. It is part of prescribing practice, not a judgment about the patient’s character.

Patients do not need to try to manage or predict what the program will show. They can help make the review more clinically useful by giving an accurate medication history, identifying prescribers and pharmacies when known, and correcting any misunderstanding during the discussion. If the record appears incomplete or inconsistent, the patient can explain the discrepancy and provide available documentation.

A monitoring-program review does not, by itself, determine whether a prescription is appropriate. Nor does it replace the clinical assessment. The prescriber must consider the patient’s presentation, treatment history, risks, and applicable law. For patients, the practical expectation is that controlled-substance prescribing may involve additional review and questions, and that a prescription is not automatic even when the appointment is established.

Chronic nonmalignant pain and the 90-day threshold

Florida Statute § 456.44 defines chronic nonmalignant pain as pain unrelated to cancer that persists beyond the usual course of a disease or injury, or more than 90 days after surgery. The 90-day period is one element of the statutory definition; it is not a standalone test that determines the diagnosis or dictates a treatment plan.

For chronic nonmalignant pain, the statute requires a physical examination and complete medical history before the initial prescription of Schedule II through IV controlled substances for that pain. This requirement is especially important when a patient expects a remote appointment to lead directly to an initial prescription. The prescriber must determine whether the required assessment has been completed and whether the circumstances allow the medication to be prescribed through the proposed care pathway.

The definition also should not be reduced to a calendar calculation. Pain that continues beyond a particular period may warrant clinical evaluation, but the cause, course, prior treatment, and effect on function remain relevant. A patient should describe the history as accurately as possible rather than trying to fit symptoms into a legal category.

For an appointment, it is reasonable to ask the practice what records are needed and whether the visit can address the patient’s immediate concern. If a physical examination or additional documentation is necessary, the practice can explain how to proceed. That answer may be less convenient than an expected prescription, but it reflects the difference between a remote discussion and a complete assessment under the applicable standard.

What to expect after the consultation

The clinician may recommend continued monitoring, a change in treatment, additional records, an in-person examination, or referral to another service. The next step should follow from the findings and the prescribing rules—not from the format of the appointment alone. Patients can ask what the plan is intended to address, what information is still missing, and when follow-up should occur.

A practical preparation sequence is straightforward:

1. Confirm that the appointment will use the practice’s required audio-video platform and ask how to reconnect if the call drops.

2. Prepare a medication list and a short timeline of pain, prior evaluations, and treatments.

3. Have relevant records available, while recognizing that the clinician may need to obtain them directly or request additional information.

4. Describe functional effects and treatment response plainly; do not alter or stop medication solely to influence the visit.

5. Ask whether the proposed plan requires an in-person assessment and what Florida’s controlled-substance rules mean for the medication under discussion.

Telehealth can make chronic-pain care more accessible, but access should not be confused with unrestricted prescribing. In Florida, medication schedule, statutory exceptions, the required history and examination, E-FORCSE review, and the limits of remote assessment all shape what can happen during and after the appointment. A reliable practice should explain those constraints clearly; a reliable assessment should be based on adequate clinical information.